Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for AnaphylmTM (dibutepinephrine) Sublingual Film

AI Briefing

• – Aquestive Therapeutics completes Type A meeting with FDA on AnaphylmTM sublingual film, receives preliminary comments.
• – Company's resubmitted NDA for Type 1 allergic reactions, including anaphylaxis treatment.
• – Aquestive Therapeutics to advance AnaphylmTM through clinical trials and regulatory review.